Diseases caused by pathologic protein folding are among the most devastating suffered by the aged. These diseases include Alzheimer's, Huntington's, Parkinson's, familial amyloid polyneuropathy, and prion. Each is a fatal disorder causing progressive cognitive and physical decline. Each is linked to aberrant folding of proteins that results in protein dysfunction. Dysfunction comes both from intrinsic changes in protein monomer structure and protein self-association (aggregation). The latter phenomenon occurs frequently in the dementing illnesses, of which Alzheimer's disease (AD) is the most common. In AD, the amyloid beta-protein (Abeta) self-associates to form oligomeric structures that circulate in plasma and cerebrospinal fluid. As the disease progresses, deposits of Aa are found in increasing number and size in the brain. These deposits, termed """"""""amyloid plaques,"""""""" contain fibrillar polymers of Abeta. Most cases of AD are not linked to mutations in the cognate structural gene for Abeta. This raises the questions of why pathologic folding and assembly of Abeta occur and why disease incidence increases so sharply after the age of 65. AD is not unique in these respects, as other dementing illnesses also are """"""""diseases of aging."""""""" The general problem area addressed by this Program Project (Program) is pathologic protein folding and assembly, as exemplified by Abeta. We hypothesize that conformational changes in Abeta lead to oligomerization and that the resulting oligomeric assemblies are the proximate neurotoxins causing AD. To test this hypothesis, we propose two long-term specific aims: 1. To understand, at the most fundamental biophysical and cellular levels, how aberrant folding of proteins produces human disease. 2. To translate this knowledge into the design and implementation of new therapeutic agents. To accomplish these aims, five principal investigators at four different American universities have joined together to create a tightly-integrated program comprising two administrative cores and five projects. Our long-term strategy seeks first to establish a cohesive and productive research enterprise focused on AD and Abeta. We make this choice because AD is the most common cause of late-life dementia, its incidence is predicted to increase significantly, and Abeta assembly has proven to be archetypal for amyloid proteins. This last point is important, because the Program is designed to advance our understanding of AD and provide new technologies applicable in studies of folding and assembly of other amyloid and non-amyloid proteins. We thus envision the significance of the Program extending beyond solely AD.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG027818-04
Application #
7663805
Study Section
Special Emphasis Panel (ZAG1-ZIJ-8 (J2))
Program Officer
Refolo, Lorenzo
Project Start
2006-09-01
Project End
2011-07-31
Budget Start
2009-08-01
Budget End
2010-07-31
Support Year
4
Fiscal Year
2009
Total Cost
$1,535,302
Indirect Cost
Name
University of California Los Angeles
Department
Neurology
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Hayden, Eric Y; Conovaloff, Joseph L; Mason, Ashley et al. (2017) Preparation of pure populations of covalently stabilized amyloid ?-protein oligomers of specific sizes. Anal Biochem 518:78-85
Zheng, Xueyun; Wu, Chun; Liu, Deyu et al. (2016) Mechanism of C-Terminal Fragments of Amyloid ?-Protein as A? Inhibitors: Do C-Terminal Interactions Play a Key Role in Their Inhibitory Activity? J Phys Chem B 120:1615-23
Yamin, Ghiam; Huynh, Tien-Phat Vuong; Teplow, David B (2015) Design and Characterization of Chemically Stabilized A?42 Oligomers. Biochemistry 54:5315-21
Williams, Thomas L; Urbanc, Brigita; Marshall, Karen E et al. (2015) Europium as an inhibitor of Amyloid-?(1-42) induced membrane permeation. FEBS Lett 589:3228-36
Hayden, Eric Y; Yamin, Ghiam; Beroukhim, Shiela et al. (2015) Inhibiting amyloid ?-protein assembly: Size-activity relationships among grape seed-derived polyphenols. J Neurochem 135:416-30
Barz, Bogdan; Urbanc, Brigita (2014) Minimal model of self-assembly: emergence of diversity and complexity. J Phys Chem B 118:3761-70
Toal, Siobhan; Meral, Derya; Verbaro, Daniel et al. (2013) pH-Independence of trialanine and the effects of termini blocking in short peptides: a combined vibrational, NMR, UVCD, and molecular dynamics study. J Phys Chem B 117:3689-706
Roychaudhuri, Robin; Yang, Mingfeng; Deshpande, Atul et al. (2013) C-terminal turn stability determines assembly differences between A?40 and A?42. J Mol Biol 425:292-308
Wu, Chun; Shea, Joan-Emma (2013) Structural similarities and differences between amyloidogenic and non-amyloidogenic islet amyloid polypeptide (IAPP) sequences and implications for the dual physiological and pathological activities of these peptides. PLoS Comput Biol 9:e1003211
Meral, Derya; Urbanc, Brigita (2013) Discrete molecular dynamics study of oligomer formation by N-terminally truncated amyloid ?-protein. J Mol Biol 425:2260-75

Showing the most recent 10 out of 68 publications